FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity-Reference-Cited by-同舟云学术

FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity

Published:2023-06 Issue:6 Volume:23 Page:463-470.e1
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Pulte Dianne,Fernandes Laura^ORCID,Wei Guo,Woods Ashley,Norsworthy Kelly J.,Gormley Nicole,Kanapuru Bindu,Gwise Thomas E.,Pazdur Richard,Schneider Julie,Theoret Marc R.,Fashoyin-Aje Lola A.,de Claro R. Angelo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference31 articles.

1. NIH Revitalization Act. Subtitle B: §131-133;1993.

2. Participation in cancer clinical trials: race-, sex-, and age-based disparities;Murthy;JAMA,2004

3. Minority participation in Gynecologic Oncology Group (GOG) studies;Scalici;Gynecol Oncol,2015

4. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials;Ailawadhi;Blood Cancer J,2018

5. FDA Analysis of racial demographics in multiple myeloma trials;Bhatnagar;Blood,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019;eClinicalMedicine;2024-05

2. Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia;JNCI: Journal of the National Cancer Institute;2024-03-22

3. Acute Myeloid Leukemia Genomics: Impact on Care and Remaining Challenges;Clinical Chemistry;2024-01

4. Disparities in acute myeloid leukemia treatments and outcomes;Current Opinion in Hematology;2023-12-07

5. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia;Haematologica;2023-08-10